Considering adjuvant therapy for stage II melanoma

Area of Science:

• Oncology
• Immunotherapy
• Dermatology

Background:

• Melanoma incidence is rising, but diagnosis occurs at earlier stages.
• Limited treatment options existed for metastatic melanoma before 2011.
• Recent therapeutic advancements have significantly improved patient survival.

Purpose of the Study:

• To review the evolution of melanoma therapeutics.
• To discuss the efficacy of novel treatments in different stages of melanoma.
• To highlight the growing importance of adjuvant therapy for stage II melanoma.

Main Methods:

• Review of clinical trial data and therapeutic advancements in melanoma.
• Analysis of survival outcomes for patients with metastatic, stage III, and stage II melanoma.
• Discussion of current standards of care and ongoing research in adjuvant therapy.

Main Results:

• Immune checkpoint inhibitors (anti-CTLA-4, anti-PD1) and BRAF/MEK inhibitors have extended survival.
• These therapies are now standard of care for resected stage III melanoma.
• Stage II melanoma patients (IIB, IIC) show survival rates comparable to some stage III patients.

Conclusions:

• Adjuvant therapy is increasingly considered for stage II melanoma patients.
• Randomized phase 3 clinical trials are evaluating expanded adjuvant therapy eligibility.
• Risk-stratification and predictive models are crucial for optimizing early-stage melanoma treatment.